Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Dalle, J-H, Balduzzi, A, Bader, P, Pieczonka, A, Yaniv, I, Lankester, A, Bierings, M, Yesilipek, A, Sedlacek, P, Ifversen, M, Svec, P, Toporski, J, Gungor, T, Wachowiak, J, Glogova, E, Poetschger, U & Peters, C 2021, 'The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG', Bone Marrow Transplantation, bind 56, nr. 1, s. 257-266. https://doi.org/10.1038/s41409-020-01014-x

APA

Dalle, J-H., Balduzzi, A., Bader, P., Pieczonka, A., Yaniv, I., Lankester, A., Bierings, M., Yesilipek, A., Sedlacek, P., Ifversen, M., Svec, P., Toporski, J., Gungor, T., Wachowiak, J., Glogova, E., Poetschger, U., & Peters, C. (2021). The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplantation, 56(1), 257-266. https://doi.org/10.1038/s41409-020-01014-x

CBE

Dalle J-H, Balduzzi A, Bader P, Pieczonka A, Yaniv I, Lankester A, Bierings M, Yesilipek A, Sedlacek P, Ifversen M, Svec P, Toporski J, Gungor T, Wachowiak J, Glogova E, Poetschger U, Peters C. 2021. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplantation. 56(1):257-266. https://doi.org/10.1038/s41409-020-01014-x

MLA

Vancouver

Author

Dalle, Jean-Hugues ; Balduzzi, Adriana ; Bader, Peter ; Pieczonka, Anna ; Yaniv, Isaac ; Lankester, Arjan ; Bierings, Marc ; Yesilipek, Akif ; Sedlacek, Petr ; Ifversen, Marianne ; Svec, Peter ; Toporski, Jacek ; Gungor, Taifun ; Wachowiak, Jacek ; Glogova, Evgenia ; Poetschger, Ulrike ; Peters, Christina. / The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. I: Bone Marrow Transplantation. 2021 ; Bind 56, Nr. 1. s. 257-266.

Bibtex

@article{1015c69082b64af38f2edebca72d961d,
title = "The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG",
abstract = "Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01-11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.",
keywords = "Child, Child, Preschool, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy, Prospective Studies, Retrospective Studies, Tissue Donors, Transplantation Conditioning, Treatment Outcome",
author = "Jean-Hugues Dalle and Adriana Balduzzi and Peter Bader and Anna Pieczonka and Isaac Yaniv and Arjan Lankester and Marc Bierings and Akif Yesilipek and Petr Sedlacek and Marianne Ifversen and Peter Svec and Jacek Toporski and Taifun Gungor and Jacek Wachowiak and Evgenia Glogova and Ulrike Poetschger and Christina Peters",
year = "2021",
month = jan,
doi = "10.1038/s41409-020-01014-x",
language = "English",
volume = "56",
pages = "257--266",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

AU - Dalle, Jean-Hugues

AU - Balduzzi, Adriana

AU - Bader, Peter

AU - Pieczonka, Anna

AU - Yaniv, Isaac

AU - Lankester, Arjan

AU - Bierings, Marc

AU - Yesilipek, Akif

AU - Sedlacek, Petr

AU - Ifversen, Marianne

AU - Svec, Peter

AU - Toporski, Jacek

AU - Gungor, Taifun

AU - Wachowiak, Jacek

AU - Glogova, Evgenia

AU - Poetschger, Ulrike

AU - Peters, Christina

PY - 2021/1

Y1 - 2021/1

N2 - Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01-11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.

AB - Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01-11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.

KW - Child

KW - Child, Preschool

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy

KW - Prospective Studies

KW - Retrospective Studies

KW - Tissue Donors

KW - Transplantation Conditioning

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85088982753&partnerID=8YFLogxK

U2 - 10.1038/s41409-020-01014-x

DO - 10.1038/s41409-020-01014-x

M3 - Journal article

C2 - 32753706

VL - 56

SP - 257

EP - 266

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -

ID: 62313495